Insider Trading Alert - IPXL, IVR And VRSK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 8, 2014, 131 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $460.00 to $19,915,560.00.

Highlighted Stocks Traded by Insiders:

Impax Laboratories (IPXL) - FREE Research Report

Hsu Larry, who is Director at Impax Laboratories, sold 219,386 shares at $26.28 on May 8, 2014. Following this transaction, the Director owned 458,568 shares meaning that the stake was reduced by 32.36% with the 219,386-share transaction.

Fleming Nigel, who is Director at Impax Laboratories, sold 4,000 shares at $26.34 on May 8, 2014. Following this transaction, the Director owned 9,699 shares meaning that the stake was reduced by 29.2% with the 4,000-share transaction.

The shares most recently traded at $25.90, down $0.44, or 1.7% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 4,000
  • 24-Week # shares sold: 7,000

The average volume for Impax Laboratories has been 788,500 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.8 billion and is part of the health care sector and drugs industry. Shares are up 4.18% year-to-date as of the close of trading on Thursday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2640.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Invesco Mortgage Capital (IVR) - FREE Research Report

King Richard J., who is President & CEO at Invesco Mortgage Capital, bought 5,500 shares at $16.99 on May 8, 2014. Following this transaction, the President & CEO owned 74,669 shares meaning that the stake was reduced by 7.95% with the 5,500-share transaction.

Kuster Robson, who is Chief Operating Officer at Invesco Mortgage Capital, bought 2,624 shares at $16.98 on May 8, 2014. Following this transaction, the Chief Operating Officer owned 17,625 shares meaning that the stake was reduced by 17.49% with the 2,624-share transaction.

The shares most recently traded at $17.02, up $0.04, or 0.24% since the insider transaction. Historical insider transactions for Invesco Mortgage Capital go as follows:

  • 4-Week # shares bought: 9,000
  • 12-Week # shares bought: 10,000
  • 24-Week # shares bought: 15,000

The average volume for Invesco Mortgage Capital has been 1.3 million shares per day over the past 30 days. Invesco Mortgage Capital has a market cap of $2.1 billion and is part of the financial sector and real estate industry. Shares are up 15.12% year-to-date as of the close of trading on Thursday.

Invesco Mortgage Capital Inc., a real estate investment trust, focuses on investing in, financing, and managing residential and commercial mortgage-backed securities and mortgage loans. The company invests in residential mortgage-backed securities for which a U.S. The stock currently has a dividend yield of 11.7%. Currently, there are 3 analysts who rate Invesco Mortgage Capital a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IVR - FREE

TheStreet Quant Ratings rates Invesco Mortgage Capital as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Invesco Mortgage Capital Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Verisk Analytics (VRSK) - FREE Research Report

Coyne Frank J, who is Director at Verisk Analytics, sold 71,228 shares at $59.83 on May 8, 2014. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 71,228-share transaction.

The shares most recently traded at $60.62, up $0.79, or 1.3% since the insider transaction. Historical insider transactions for Verisk Analytics go as follows:

  • 12-Week # shares sold: 1,500
  • 24-Week # shares sold: 1,500

The average volume for Verisk Analytics has been 950,000 shares per day over the past 30 days. Verisk Analytics has a market cap of $9.9 billion and is part of the services sector and diversified services industry. Shares are down 8.4% year-to-date as of the close of trading on Thursday.

Verisk Analytics, Inc. provides proprietary data, analytic methods, and embedded decision support solutions for detecting fraud in property and casualty (P&C) insurance, financial, and healthcare industries in the United States. The company has a P/E ratio of 29.4. Currently, there are 11 analysts who rate Verisk Analytics a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRSK - FREE

TheStreet Quant Ratings rates Verisk Analytics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Verisk Analytics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Impax Shares Jump on Merger Buzz

Impax Shares Jump on Merger Buzz

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Teva, Mylan Seen to Stay on M&A Sidelines

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva's Massive Debt Load Just Became an Even Bigger Issue